Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C WARREN

Showing results (721-730 of 1,118) with videos related to

Pageof 112
Sort By:
European Journal of Pharmacology|August 8, 1998
The effects of the novel benzodiazepine receptor inverse agonist Ru 34000 on ethanol-maintained behaviorsH L June, M W Eggers, C Warren-Reese, et al.
Analytical Chemistry|November 25, 2025
Hybrid Vernier Sensor Based on Fabry-Perot-Assisted Tapered Microfiber for Ultrasensitive Detection of Nucleic Acid BiomarkersMinglu Yan, Dongqi Yan, Ya-Nan Zhang, et al.
Nature Communications|July 8, 2026
A single-cell atlas of porcine hematopoietic developmentWeihong Gu, Yuhan Wen, Yi Huang, et al.
Annals of Neurology|June 29, 2010
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD studyFabrizio Stocchi, Olivier Rascol, Karl Kieburtz, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Exploring Cancer in Colorado using a novel data platform: the ECCO experienceJan T Lowery, Faisal Alquaddoomi, Vince Rubinetti, et al.
Clinical Neuropharmacology|July 15, 2004
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)C Warren Olanow, Philippe Damier, Christopher G Goetz, et al.
Postgraduate Medical Journal|December 24, 2008
Improvement in the management of acutely poisoned patients using an electronic database, prospective audit and targeted educational interventionS L Greene, D M Wood, I B Gawarammana, et al.
The Lancet. Neurology|November 18, 2006
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trialC Warren Olanow, Anthony H V Schapira, Peter A LeWitt, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Placebo influences on dyskinesia in Parkinson's diseaseChristopher G Goetz, Eugene Laska, Christine Hicking, et al.
Genome Biology|December 19, 2014
Conserved syntenic clusters of protein coding genes are missing in birdsPeter V Lovell, Morgan Wirthlin, Larry Wilhelm, et al.
Pageof 112

Showing results (721-730 of 1,118) with videos related to

Sort By:
Pageof 112
European Journal of Pharmacology|August 8, 1998
The effects of the novel benzodiazepine receptor inverse agonist Ru 34000 on ethanol-maintained behaviorsH L June, M W Eggers, C Warren-Reese, et al.
Analytical Chemistry|November 25, 2025
Hybrid Vernier Sensor Based on Fabry-Perot-Assisted Tapered Microfiber for Ultrasensitive Detection of Nucleic Acid BiomarkersMinglu Yan, Dongqi Yan, Ya-Nan Zhang, et al.
Nature Communications|July 8, 2026
A single-cell atlas of porcine hematopoietic developmentWeihong Gu, Yuhan Wen, Yi Huang, et al.
Annals of Neurology|June 29, 2010
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD studyFabrizio Stocchi, Olivier Rascol, Karl Kieburtz, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Exploring Cancer in Colorado using a novel data platform: the ECCO experienceJan T Lowery, Faisal Alquaddoomi, Vince Rubinetti, et al.
Clinical Neuropharmacology|July 15, 2004
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)C Warren Olanow, Philippe Damier, Christopher G Goetz, et al.
Postgraduate Medical Journal|December 24, 2008
Improvement in the management of acutely poisoned patients using an electronic database, prospective audit and targeted educational interventionS L Greene, D M Wood, I B Gawarammana, et al.
The Lancet. Neurology|November 18, 2006
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trialC Warren Olanow, Anthony H V Schapira, Peter A LeWitt, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Placebo influences on dyskinesia in Parkinson's diseaseChristopher G Goetz, Eugene Laska, Christine Hicking, et al.
Genome Biology|December 19, 2014
Conserved syntenic clusters of protein coding genes are missing in birdsPeter V Lovell, Morgan Wirthlin, Larry Wilhelm, et al.
Pageof 112